Crispr Therapeutics Board Director Simeon George Purchases $51.5 Million in Shares
ByAinvest
Sunday, Jul 20, 2025 1:51 am ET1min read
CRSP--
The purchase was disclosed in an SEC filing, indicating that Simeon bought 989,812 shares at a price of $52.03 each [4]. This substantial investment by an insider has sparked interest among investors, contributing to the stock's recent performance.
Analysts have mixed views on CRISPR Therapeutics' future prospects. While the average target price is projected at $80.84, with high estimates at $268.00 and lows at $32.00, the average brokerage recommendation is a solid 2.2, translating to an "Outperform" rating [3]. GuruFocus offers a more conservative estimate, setting the GF Value at $36.68, implying a potential downside of 41.66% from the current price of $62.875 [3].
Despite the stock's recent gains, CRISPR Therapeutics reported a net loss of $136 million in the first quarter of 2025, with revenues jumping by 71.6% to $865 million [4]. The company is expected to release its second quarter earnings performance in the first week of August 2025.
References:
[1] https://www.sec.gov/Archives/edgar/data/1674416/000095017025096666/xslF345X05/ownership.xml
[2] https://seekingalpha.com/news/4468897-crispr-director-george-buys-515m-of-shares
[3] https://www.gurufocus.com/news/2987913/crsp-surges-after-major-stock-purchase-by-board-director
[4] https://finance.yahoo.com/news/crispr-therapeutics-crsp-soars-18-181654598.html
Crispr Therapeutics (NASDAQ:CRSP) disclosed a $51.5 million stock purchase by board director Simeon George in an SEC filing. The company's stock surged as much as 21% on Friday, marking its biggest intraday gain since February, and is now up around 58.4% year-to-date.
Crispr Therapeutics (NASDAQ:CRSP) experienced a significant stock surge following a major insider purchase. On July 16, 2025, the company's board director, George Simeon, purchased $51.5 million worth of shares [2]. The stock surged by as much as 21% on Friday, marking its biggest intraday gain since February [3]. As a result, the stock is now up around 58.4% year-to-date [2].The purchase was disclosed in an SEC filing, indicating that Simeon bought 989,812 shares at a price of $52.03 each [4]. This substantial investment by an insider has sparked interest among investors, contributing to the stock's recent performance.
Analysts have mixed views on CRISPR Therapeutics' future prospects. While the average target price is projected at $80.84, with high estimates at $268.00 and lows at $32.00, the average brokerage recommendation is a solid 2.2, translating to an "Outperform" rating [3]. GuruFocus offers a more conservative estimate, setting the GF Value at $36.68, implying a potential downside of 41.66% from the current price of $62.875 [3].
Despite the stock's recent gains, CRISPR Therapeutics reported a net loss of $136 million in the first quarter of 2025, with revenues jumping by 71.6% to $865 million [4]. The company is expected to release its second quarter earnings performance in the first week of August 2025.
References:
[1] https://www.sec.gov/Archives/edgar/data/1674416/000095017025096666/xslF345X05/ownership.xml
[2] https://seekingalpha.com/news/4468897-crispr-director-george-buys-515m-of-shares
[3] https://www.gurufocus.com/news/2987913/crsp-surges-after-major-stock-purchase-by-board-director
[4] https://finance.yahoo.com/news/crispr-therapeutics-crsp-soars-18-181654598.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet